Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
Acute, Double-blind, Adaptively Randomized Treatment With Duloxetine or Escitalopram, Followed by Open-label Naturalistic Follow-up.
University of Cincinnati
60 participants
Jan 1, 2020
INTERVENTIONAL
Conditions
Summary
Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by open-label naturalistic follow-up.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Encapsulated duloxetine 30 mg, 60 mg; once-daily
Encapsulated escitalopram 5 mg, 10 mg, 15 mg, 20 mg; once-daily
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04245436